Westlake Chemical Partners (WLKP) has wrapped up FY 2025 with Q4 revenue of US$323.0 million and EPS of US$0.41, with trailing twelve month revenue at US$1.2 billion and EPS of US$1.38 framing the latest numbers. The company has seen quarterly revenue range from US$237.6 million to US$323.0 million over the year while EPS moved from US$0.14 in Q1 2025 to around US$0.41 in each of the last three quarters, setting up a picture where net margin compression and softer earnings trends are key parts of the story investors are reacting to today.
See our full analysis for Westlake Chemical Partners.With the headline figures on the table, the next step is to see how these results line up with the widely held narratives about Westlake Chemical Partners, and where the numbers may be pushing investors to rethink the story.
Curious how numbers become stories that shape markets? Explore Community Narratives
Margins Tighten With 4.2% Net Profit Level
- Over the last 12 months, net profit margin sat at 4.2% compared with 5.5% a year earlier, while trailing net income was US$48.7 million on US$1.17b of revenue, showing that only a small slice of sales is flowing through to the bottom line.
- What stands out for a more bearish take is that earnings have declined at an annualized 8.1% over the past five years, and the latest trailing margin compression lines up with that concern:
- Bears point to the drop in trailing margin from 5.5% to 4.2% as evidence that profitability is under pressure even with revenue at about US$1.17b.
- The fact that TTM EPS is US$1.38 versus higher levels a year earlier supports the cautious view that earnings power has weakened rather than strengthened recently.
Revenue Pace Trails Market At 6.8%
- Revenue on a trailing basis is cited as growing at 6.8% per year compared with a 10.3% per year figure for the broader US market. Even with quarterly revenue moving from US$237.6 million in Q1 2025 to US$323.0 million in Q4 2025, the growth profile is described as slower than the market benchmark.
- For a bullish angle, the income-oriented narrative that focuses on stability is partly tested by these growth numbers:
- Supporters who like the steady quarterly range of about US$297.1 million to US$323.0 million in the last three quarters may see that consistency as fitting an infrastructure-style story, even if the 6.8% revenue pace is behind the 10.3% US figure.
- At the same time, the long-run 8.1% annual earnings decline and the drop in trailing EPS from US$1.77 a year ago to US$1.38 today challenge any bullish claim that moderate revenue growth alone is enough to keep earnings resilient.
Valuation Gap Versus 16x P/E And DCF Fair Value
- Shares trade at US$22.08 with a P/E of 16x, compared with peer and US Chemicals industry P/E levels of 27.3x and 25.8x, and a DCF fair value of about US$71.87, so the current price sits well below both the multiple and DCF references.
- For investors weighing a more optimistic story, the numbers create a tension between weaker earnings trends and a wide valuation gap:
- On one hand, the P/E discount and the large gap between US$22.08 and the US$71.87 DCF fair value can support a bullish view that the market is pricing in a lot of caution already.
- On the other hand, trailing earnings of US$48.7 million and a 4.2% net margin, combined with high debt and an 8.54% dividend that is not well covered by earnings, give bears specific figures to point to when they argue that the discount may reflect balance sheet and payout risks.
Next Steps
Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Westlake Chemical Partners's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.
Given the mixed signals around growth, margins, and valuation, it is worth moving quickly, reviewing the full data, and weighing 1 key reward and 3 important warning signs for yourself.
See What Else Is Out There
Westlake Chemical Partners is dealing with shrinking margins, weaker earnings trends, a high dividend that is not covered by earnings, and balance sheet concerns tied to debt.
If that mix of pressure points feels uncomfortable, move quickly and check out solid balance sheet and fundamentals stocks screener (40 results) to focus on companies where financial strength and coverage of obligations are front and center.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com